VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in a Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company's system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits.
Cyborg Score Rationale
Needham analyst Joseph Stringer raised the price target for Vaxcyte from $90 to $110 and maintained a Buy rating on the stock, highlighting it as a Top Pick for 2026. The firm reflected on the topline readout from the Phase 3 OPUS-1 trial, expected in the fourth quarter of 2026, with a planned BLA filing the following year.
Top Insights
Vaxcyte announced the closing of $632.5 million public offering in February 2026, providing substantial cash runway for clinical development.
OPUS-1 Phase 3 trial topline expected in Q4 2026 with BLA filing in 2027; OPUS-2 and OPUS-3 trials with results expected in H1 2027.
VAX-31 is designed to cover ~95% of IPD and ~88% of pneumococcal pneumonia in U.S. adults 50+, with incremental coverage vs. standard-of-care of 14–34% (IPD) and 19–31% (pneumonia).
Vaxcyte plans North Carolina fill-finish buildout beginning Q1 2026 as part of a long-term commitment of up to $1 billion in U.S. manufacturing and services.